ADMA Biologics
ADMA
252 hedge funds and large institutions have $2.03B invested in ADMA Biologics in 2024 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 88 increasing their positions, 84 reducing their positions, and 18 closing their positions.
2,302% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $527K
228% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 18
28% more capital inflows, than outflows
Capital inflows: $263M | Capital outflows: $206M
18% more funds holding
Funds holding: 214 → 252 (+38)
1.41% more ownership
Funds ownership: 76.74% → 78.14% (+1.4%)
5% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 84
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$45M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.3M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
-$30.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20.9M |
| 3 |
OAM
Ophir Asset Management
Sydney,
Australia
|
-$13.4M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$13.1M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$12.9M |
ADMA Hedge Fund Activity: Q2 2024 in Review
252 of the 6,941 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2024, worth a combined $2.03B — up 75% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new ADMA positions and 18 closed out — a net gain of 41 holders — while 88 added to existing stakes and 84 trimmed.
The largest buyer was Invesco, adding an estimated $45M. The largest seller was Perceptive Advisors, cutting an estimated $30.7M.
- 252 institutional investors held ADMA Biologics (ADMA) as of Q2 2024, up from 214 in Q1 2024.
- Funds reported $2.03B of ADMA Biologics stock for Q2 2024, up 75% quarter-over-quarter.
- 59 funds opened new ADMA Biologics positions in Q2 2024 and 18 closed out, a net change of +41 holders.
- The largest ADMA Biologics buyer in Q2 2024 was Invesco, an estimated $45M added.
- The largest ADMA Biologics seller in Q2 2024 was Perceptive Advisors, an estimated $30.7M sold.
Based on aggregated 13F filings for Q2 2024.